These findings indicate that targeting E2F1-lncRNA interactions and their downstream molecules might be feasible strategies for overcoming gefitinib resistance, which provides fresh insights into the treatment of advanced NSCLC patients. Here, E2F1 is linked to non-small cell lung carcinoma.